485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

Home・Akcijų sąrašas・AB Science SA

AB Science SA

Uždarymo kaina

1.198 2.92

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.162

Max

1.202

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.2M
Pardavimai	515K
Pelno marža	-1,005.243
Darbuotojai	36
EBITDA	-2.5M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	79M
Ankstesnė atidarymo kaina	-1.72
Ankstesnė uždarymo kaina	1.198

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.426 / 1.448 Palaikymas ir pasipriešinimas

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-14 23:36; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026-04-14 23:24; UTC

Karštos akcijos

Stocks to Watch: Gloo, Broadcom, GitLab

2026-04-14 22:42; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026-04-14 21:32; UTC

Pagrindinės rinkos jėgos

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026-04-14 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026-04-14 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-04-14 22:54; UTC

Uždarbis

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026-04-14 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026-04-14 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026-04-14 22:14; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026-04-14 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026-04-14 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026-04-14 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-04-14 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 20:32; UTC

Karštos akcijos

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026-04-14 19:59; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026-04-14 19:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-14 19:09; UTC

Įsigijimai, susijungimai, perėmimai

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026-04-14 18:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-14 18:30; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių AB Science SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.